Odak Mihir, Douedi Steven, Mararenko Anton, Alshami Abbas, Elkherpitawy Islam, Douedi Hani, Zacks Eran, Sealove Brett
Department of Internal Medicine, Jersey Shore University Medical Center, Neptune, NJ 07753, USA.
Department of Cardiology, Deborah Heart and Lung Center, Browns Mills, NJ 08015, USA.
Cardiol Res. 2022 Aug;13(4):177-184. doi: 10.14740/cr1373. Epub 2022 Aug 15.
Arrhythmogenic right ventricular cardiomyopathy (ARVC) is a predominantly autosomal dominant genetic condition in which fibrous and fatty tissue infiltrate and replace healthy myocardial tissue. This uncommon yet debilitating condition can cause ventricular arrhythmias, cardiac failure, and sudden cardiac death. Management focuses primarily on prevention of syndrome sequelae in order to prevent morbidity and mortality. Genetic testing and screening in affected families, although utilized clinically, has not yet been incorporated in guidelines due to lack of larger studies and data. We aim herein to identify causative gene mutations, present advancements in diagnosis and management, and describe the role of genetic screening and counseling in patients with ARVC. With the advancement of genetic testing and therapy, diseases such as ARVC may become more accurately diagnosed and more effectively managed, ultimately significantly reducing morbidity and mortality.
致心律失常性右室心肌病(ARVC)是一种主要为常染色体显性遗传的疾病,其中纤维组织和脂肪组织浸润并取代健康的心肌组织。这种罕见但使人衰弱的疾病可导致室性心律失常、心力衰竭和心源性猝死。治疗主要侧重于预防综合征后遗症,以防止发病和死亡。对受影响家庭进行基因检测和筛查,虽然已在临床中使用,但由于缺乏更大规模的研究和数据,尚未纳入指南。我们在此旨在确定致病基因突变,介绍诊断和治疗方面的进展,并描述基因筛查和咨询在ARVC患者中的作用。随着基因检测和治疗的进展,诸如ARVC等疾病可能会得到更准确的诊断和更有效的治疗,最终显著降低发病率和死亡率。